CGON
CG Oncology, Inc. Common stock
NASDAQ · Healthcare · Biotechnology · US
$74.67
+0.46%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 6.2M | 4.0M | 1.1M | 204.0K | 191.0K |
| Cost of Revenue | 11.4M | 4.6M | 82.1M | 45.8M | 15.0K |
| Gross Profit | (5.2M) | (607.0K) | (81.0M) | (45.5M) | 176.0K |
| Operating Expenses | |||||
| R&D Expense | 156.2M | 116.6M | 82.1M | 45.8M | 29.0M |
| SG&A Expense | 91.1M | 73.5M | 33.7M | 9.9M | 6.4M |
| General & Admin Expense | 91.1M | 73.5M | 33.7M | 9.9M | 6.4M |
| Selling & Marketing Expense | — | — | — | — | (15.0K) |
| Other Expenses | 155.0K | — | (82.1M) | (45.8M) | — |
| Total Operating Expenses | 247.5M | 190.2M | 33.7M | 9.9M | 35.4M |
| Cost and Expenses | 258.8M | 194.8M | 115.8M | 55.7M | 35.4M |
| Operating Income (EBIT) | (252.6M) | (190.8M) | (114.7M) | (55.4M) | (35.2M) |
| Non-Operating | |||||
| Interest Income | 43.5M | 29.9M | 26.6M | 6.9M | — |
| Interest Expense | — | — | — | — | 1.0K |
| Net Interest Income | 43.5M | 29.9M | 26.6M | 6.9M | (1.0K) |
| Other Non-Op Income/Expense | 28.2M | 29.8M | 26.6M | 6.8M | (197.0K) |
| Non-Operating Income (excl Interest) | (28.2M) | (29.8M) | (26.6M) | (6.8M) | 196.0K |
| EBT (Pre-Tax Income) | (224.4M) | (161.0M) | (88.0M) | (48.6M) | (35.4M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (224.4M) | (161.0M) | (88.0M) | (48.6M) | (35.4M) |
| Earnings from Cont. Ops | (224.4M) | (161.0M) | (88.0M) | (48.6M) | (35.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (224.4M) | (161.0M) | (88.0M) | (67.8M) | (43.8M) |
| Per Share | |||||
| Basic EPS | ($2.70) | ($2.08) | ($1.41) | ($1.02) | ($0.66) |
| Diluted EPS | ($2.70) | ($2.08) | ($1.41) | ($1.02) | ($0.66) |
| Revenue Per Share | $0.07 | $0.05 | $0.02 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 88.2M | 77.3M | 62.5M | 66.6M | 66.6M |
| Diluted Shares Outstanding | 88.2M | 77.3M | 62.5M | 66.6M | 66.6M |
| Profitability Metrics | |||||
| EBITDA | (222.3M) | (159.6M) | (88.0M) | (48.6M) | (35.4M) |
| D&A | 2.1M | 1.4M | 32.0K | 17.0K | 15.0K |
| EBIT | (224.4M) | (161.0M) | (88.0M) | (48.6M) | (35.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026